Safety and Efficacy of Enhanced Recovery After Surgery in Neurocritical Care
Launched by SHANGHAI 6TH PEOPLE'S HOSPITAL · Jan 27, 2024
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new approach called Enhanced Recovery After Surgery (ERAS) for patients in neurocritical care, particularly those recovering from serious conditions like traumatic brain injury or strokes. ERAS focuses on better management before, during, and after surgery to help patients heal faster, reduce complications, and shorten their hospital stay. The goal of the study is to find the best ways to implement ERAS for patients undergoing neurosurgery, providing more evidence on its safety and effectiveness.
To participate in this trial, participants need to be between 18 and 75 years old and have a moderate to severe brain injury or cerebrovascular disease that requires intensive surgical treatment. They should expect to stay in the hospital for at least one week, and their caregivers must be able to understand and agree to the study. However, patients who are not having surgery, are brain dead shortly after admission, or have certain severe conditions may not be eligible. Overall, this study aims to improve recovery for those in need of neurosurgical care by applying proven methods that have worked well in other types of surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18-75 years old
- • Patients with moderate or severe acute traumatic brain injury or cerebrovascular disease requiring neurosurgical intensive care treatment
- • Hospitalization time ≥ 1 week
- • The guardian is able to understand and actively cooperate in completing the project
- • The guardian signs an informed consent form
- Exclusion Criteria:
- • Patients undergoing non-surgical treatment
- • Patients diagnosed as brain death within the first 24 hours after admission to NICU
- • Patients undergoing cardiopulmonary resuscitation, maintenance dialysis, end-stage tumors, and disseminated cancer
- • Patients who withdraw treatment during hospitalization or are discharged automatically
- • Patients who underwent unplanned secondary surgery during the research process
- • Individuals who cannot be followed up during the research process
About Shanghai 6th People's Hospital
Shanghai 6th People's Hospital is a leading medical institution in China, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital focuses on a wide range of therapeutic areas, striving to enhance patient outcomes and contribute to medical knowledge. With a dedicated team of experienced researchers and clinicians, Shanghai 6th People's Hospital emphasizes rigorous scientific methodology and ethical standards, ensuring that all trials are conducted with the utmost integrity and patient safety in mind. Through collaboration with various stakeholders, the hospital aims to bridge the gap between clinical research and real-world application, ultimately improving healthcare delivery both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, , China
Patients applied
Trial Officials
Hao Chen, M.D., Ph.D.
Study Director
Shanghai 6th Peoples' Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported